Fate Therapeutics, Inc. (FATE) vs Upstream Bio, Inc. (UPB)

Fate Therapeutics, Inc. and Upstream Bio, Inc. are both Biotechnology companies. Fate Therapeutics, Inc. and Upstream Bio, Inc. are of similar size ($283.2M and $279.2M). Upstream Bio, Inc. grew revenue faster over the last twelve months: 16.0% against −23.4%. Fate Therapeutics, Inc. has the higher net margin (−1,941.1% vs −4,955.7%) and the higher return on invested capital (0.00% vs −1,100.9%). Across the 15 metrics below, Fate Therapeutics, Inc. leads on 9 and Upstream Bio, Inc. on 6.

Valuation

Metric FATE UPB Biotechnology median
P/E n/m n/m 7.88
P/S 43.59 92.62 11.47
P/B 1.84 1.08 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 36.07 9.87 10.73
Earnings yield (44.68%) (54.10%) (28.84%)
Free cash flow yield (37.26%) (46.74%) (23.03%)

Profitability

Metric FATE UPB Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (2,058.08%) (5,382.65%) 0.00%
Net margin (1,941.09%) (4,955.67%) 0.00%
Free cash flow margin (1,624.06%) (4,317.42%) 0.00%
Return on equity (60.75%) (46.05%) (57.72%)
Return on assets (39.89%) (44.61%) (49.22%)
Return on invested capital 0.00% (1,100.93%) 0.00%

Growth

Metric FATE UPB Biotechnology median
Revenue growth (TTM) (23.36%) 15.98% 5.64%
EPS growth (last fiscal year) 29.88% 52.33% —
Revenue growth, 5-year CAGR (26.71%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric FATE UPB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.85 27.99 4.73
Net debt to EBITDA 1.47 2.11 0.96

Dividend

Metric FATE UPB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric FATE UPB Biotechnology median
Market cap 279.18m 283.17m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack